evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
JOURNAL OF CLINICAL ONCOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要